Department of Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich.
Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston.
Int J Surg. 2023 Dec 1;109(12):4238-4262. doi: 10.1097/JS9.0000000000000688.
Surgeons have historically used age as a preoperative predictor of postoperative outcomes. Sarcopenia, the loss of skeletal muscle mass due to disease or biological age, has been proposed as a more accurate risk predictor. The prognostic value of sarcopenia assessment in surgical patients remains poorly understood. Therefore, the authors aimed to synthesize the available literature and investigate the impact of sarcopenia on perioperative and postoperative outcomes across all surgical specialties.
The authors systematically assessed the prognostic value of sarcopenia on postoperative outcomes by conducting a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching the PubMed/MEDLINE and EMBASE databases from inception to 1st October 2022. Their primary outcomes were complication occurrence, mortality, length of operation and hospital stay, discharge to home, and postdischarge survival rate at 1, 3, and 5 years. Subgroup analysis was performed by stratifying complications according to the Clavien-Dindo classification system. Sensitivity analysis was performed by focusing on studies with an oncological, cardiovascular, emergency, or transplant surgery population and on those of higher quality or prospective study design.
A total of 294 studies comprising 97 643 patients, of which 33 070 had sarcopenia, were included in our analysis. Sarcopenia was associated with significantly poorer postoperative outcomes, including greater mortality, complication occurrence, length of hospital stay, and lower rates of discharge to home (all P <0.00001). A significantly lower survival rate in patients with sarcopenia was noted at 1, 3, and 5 years (all P <0.00001) after surgery. Subgroup analysis confirmed higher rates of complications and mortality in oncological (both P <0.00001), cardiovascular (both P <0.00001), and emergency ( P =0.03 and P =0.04, respectively) patients with sarcopenia. In the transplant surgery cohort, mortality was significantly higher in patients with sarcopenia ( P <0.00001). Among all patients undergoing surgery for inflammatory bowel disease, the frequency of complications was significantly increased among sarcopenic patients ( P =0.007). Sensitivity analysis based on higher quality studies and prospective studies showed that sarcopenia remained a significant predictor of mortality and complication occurrence (all P <0.00001).
Sarcopenia is a significant predictor of poorer outcomes in surgical patients. Preoperative assessment of sarcopenia can help surgeons identify patients at risk, critically balance eligibility, and refine perioperative management. Large-scale studies are required to further validate the importance of sarcopenia as a prognostic indicator of perioperative risk, especially in surgical subspecialties.
外科医生历来将年龄作为术后结果的术前预测指标。由于疾病或生物年龄导致的骨骼肌质量丧失的肌少症已被提出作为更准确的风险预测指标。肌少症评估在外科患者中的预后价值仍知之甚少。因此,作者旨在综合现有文献,并调查肌少症对所有外科专业的围手术期和术后结果的影响。
作者根据系统评价和荟萃分析的首选报告项目(PRISMA)指南,系统评估了肌少症对术后结果的预后价值,检索了从创建到 2022 年 10 月 1 日的 PubMed/MEDLINE 和 EMBASE 数据库。他们的主要结局是并发症发生、死亡率、手术和住院时间、出院回家和术后 1、3 和 5 年的生存率。根据 Clavien-Dindo 分类系统对并发症进行分层分析。敏感性分析通过关注具有肿瘤学、心血管、急诊或移植手术人群的研究以及具有更高质量或前瞻性研究设计的研究来进行。
共纳入了 294 项研究,共纳入了 97643 名患者,其中 33070 名患者患有肌少症。肌少症与术后结局较差显著相关,包括死亡率、并发症发生率、住院时间较长,以及出院回家的比例较低(均 P <0.00001)。手术后 1、3 和 5 年,肌少症患者的生存率明显较低(均 P <0.00001)。亚组分析证实,肿瘤学(均 P <0.00001)、心血管(均 P <0.00001)和急诊患者( P =0.03 和 P =0.04)的肌少症患者并发症和死亡率更高。在移植手术队列中,肌少症患者的死亡率明显更高( P <0.00001)。在所有接受炎症性肠病手术的患者中,肌少症患者的并发症发生率明显增加( P =0.007)。基于高质量研究和前瞻性研究的敏感性分析表明,肌少症仍然是死亡率和并发症发生的显著预测因素(均 P <0.00001)。
肌少症是外科患者结局较差的重要预测指标。术前评估肌少症可以帮助外科医生识别风险患者,严格评估资格,并改善围手术期管理。需要进行大规模研究来进一步验证肌少症作为围手术期风险预后指标的重要性,尤其是在外科亚专业领域。